Source disclosure: February 13, 2026
GNI Group Ltd. [2160.T]
TOKYO, Feb 13 (Pulse News Wire) – GNI Group Ltd. (2160.T) announced today that it will delay the release of its fiscal year 2026 consolidated earnings forecast and accompanying briefing materials due to concerns over fair disclosure regulations related to its U.S.-listed subsidiary, Gyre Therapeutics, Inc.
Additionally, the previously scheduled investor briefing for February 24, 2026, has also been postponed. The primary reason for the delay is to ensure compliance with fair disclosure requirements. Gyre Therapeutics plans to announce its quarterly results in mid-March, and disclosing detailed segment information and business outlook prior to their official announcement could violate securities regulations. Furthermore, the timing of NDA approval for chronic hepatitis B-induced liver fibrosis treatment drug F351, pricing assumptions, and the progress of research and development by Cullgen Inc.
Make accurate forecasting challenging at this stage. In light of these circumstances, GNI Group believes strict adherence to compliance standards is crucial for maximizing shareholder value, particularly given the significance of the F351 project. The company intends to promptly disclose the forecast once reasonable estimates can be made after Gyre Therapeutics' earnings release. Investors are urged to consider GNI Group's commitment to transparency and fairness during this process.
AI-translated content. 🟢 Confidence: High See terms • Original filing